Alexander Hardy MBA, MA

Alexander Hardy became Genentech’s Chief Executive Officer on March 1, 2019. Previously, he was head of Global Product Strategy, Roche Pharmaceuticals and served in a number of key leadership positions across Genentech and Roche for over 13 years. Mr. Hardy led cross-functional teams to develop and launch new medicines and indications in more than 100 countries worldwide. He also co-chaired Roche’s late-stage portfolio committee, with direct accountability for new formulations and devices, geographic expansion, and post-marketing investments. From 2014 to 2016.

Mr. Hardy was head of Asia Pacific for Roche Pharmaceuticals, overseeing 19 countries and more than 6,000 employees. Prior to this, starting in 2005 he held several senior management positions at Genentech, including heading patient access services and leading commercial operations for a range of medicines and therapeutic areas from HER2-positive cancer to influenza and neuroscience. Prior to Genentech, Mr. Hardy held leadership positions at Novartis as head of market access for Europe, country head for Denmark, and business unit head and director of strategic planning and new product development in the UK. Mr. Hardy completed his undergraduate education at Cambridge University in the UK and earned his MBA at the University of Michigan.